An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy

BACKGROUND: For lung adenocarcinoma (LUAD) patients receiving platinum-based adjuvant chemotherapy (ACT), predictive signatures extracted from survival data solely are not directly associated with platinum response. Another limitation of reported signatures, commonly based on risk scores summarised...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Lishuang, Li, Yang, Qin, Yuan, Shi, Gengen, Li, Tianhao, Wang, Jiasheng, Chen, Libin, Gu, Yunyan, Zhao, Wenyuan, Guo, Zheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155365/
https://www.ncbi.nlm.nih.gov/pubmed/27855439
http://dx.doi.org/10.1038/bjc.2016.370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155365/
https://www.ncbi.nlm.nih.gov/pubmed/27855439
http://dx.doi.org/10.1038/bjc.2016.370

Ejemplares similares